Long-acting parathyroid hormone treatment for hypoparathyroidism
Long-acting PTH for hypoparathyroidism
A long-lasting parathyroid hormone medicine designed to help people with hypoparathyroidism keep their calcium levels steady and take fewer pills.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Extend Biosciences, INC. NIH-funded |
| Lab location | 1 site (Newton, UNITED STATES) |
| Project ID | NIH-11179115 on NIH RePORTER |
What this research studies
This project is developing a long-acting form of parathyroid hormone (PTH) to replace missing hormone in people with hypoparathyroidism. Researchers will study how the drug is absorbed, distributed, metabolized, and eliminated and will measure blood levels of calcium, phosphorus, and markers of bone turnover. Safety checks will include monitoring for heart rhythm changes, kidney effects, and other adverse events. The aim is to mimic natural PTH activity so patients need less oral calcium and active vitamin D and face fewer long-term complications.
Who could benefit from this research
Good fit: Adults with chronic hypoparathyroidism who currently rely on supplemental calcium and active vitamin D and who are willing to attend clinic visits for monitoring would be ideal candidates.
Not a fit: People without hypoparathyroidism, or those with medical contraindications to PTH therapy (for example certain cancers or severe uncontrolled conditions), are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, the treatment could keep calcium levels more stable, reduce daily pill burden, and lower risks of kidney stones, soft-tissue calcifications, and bone problems.
How similar studies have performed: Continuous pump delivery of PTH has shown the ability to normalize calcium and bone markers in prior trials, while long-acting injectable PTH formulations are newer and less proven.
Where this research is happening
Newton, UNITED STATES
- Extend Biosciences, INC. — Newton, United States (Active)
Researchers
- Principal investigator: Hales, Laura M — Extend Biosciences, INC.
- Study coordinator: Hales, Laura M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.